Blitz Bureau
NEW DELHI: India seeks closer cooperation among the world’s medicine regulators, supported by its expanding network of trade agreements, Commerce and Industry Minister Piyush Goyal said on July 31.
This will enable faster access to high-quality, affordable medicines for patients worldwide while strengthening India’s position as a global hub for pharmaceutical innovation, the minister posted on X.
The two-day ‘Global Drug Regulatory Conclave 2026’ commenced in Bharat Mandapam here and as India’s flagship international forum on pharmaceutical regulatory cooperation and convergence, “the conclave brings together the heads and senior officials of national drug regulatory authorities from across the world,” Goyal noted.
He wished the conclave great success in fostering deeper collaboration among the Indian pharmaceutical industry, global regulators, and stakeholders, paving the way for a more resilient, innovative, and patient-centric global healthcare ecosystem.
Goyal said the Global Drug Regulatory Conclave 2026 will strengthen international cooperation and reinforce India’s position as a global pharmaceutical innovation hub.
Meanwhile, the ‘GDRC 2026’, organised by Pharmexcil, focuses on strengthening India’s pharmaceutical regulatory ecosystem.
India is building a future-ready drug regulatory framework to accelerate healthcare innovation while maintaining the highest standards of patient safety, quality, and efficacy, health Minister J.P. Nadda said in his virtual address earlier.
The Drugs Controller General of India (DCGI) Dr Rajeev Singh Raghuvanshi said the Central Drugs Standard Control Organisation (CDSCO) will roll out the first phase of an end-to-end digital drug regulatory platform within the next 18 months, marking a significant step in modernising India’s pharmaceutical regulatory ecosystem.
